Short description
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for cancer and macular degeneration.
Description
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 2006
Exited on
January 30, 2015
Went public on
January 30, 2015
Stock symbol
TCON
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Noaccess, Absolutely Noaccess, No Way, Absolutely Noaccess, Noaccess, Noaccess, Noaccess, Noaccess, Absolutely Noaccess
Sign in for full access
Founders
Charles P. Theuer